To date, it has been shown that, in BA, IBD, and rheumatoid arthritis, TL1A also stimulates ILC2 to form their disease condition, suggesting that TL1A also has the ability to activate the skin resident ILC2 [19,20,31]. This evidence concerns the gene TNFSF15 and breast angiosarcoma.